TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06948214: Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Sponsor: Lumos Pharma · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 150 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT06948214 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06948214 Rescue Dossier →